JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M504860200 on October 31, 2005

J. Biol. Chem., Vol. 281, Issue 1, 334-340, January 6, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/1/334    most recent
M504860200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuwahara, T.
Right arrow Articles by Iwatsubo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuwahara, T.
Right arrow Articles by Iwatsubo, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Familial Parkinson Mutant {alpha}-Synuclein Causes Dopamine Neuron Dysfunction in Transgenic Caenorhabditis elegans*{boxs}

Tomoki Kuwahara{ddagger}1, Akihiko Koyama{ddagger}1, Keiko Gengyo-Ando§, Mayumi Masuda¶, Hisatomo Kowa{ddagger}, Makoto Tsunoda¶, Shohei Mitani§, and Takeshi Iwatsubo{ddagger}2

From the Departments of {ddagger}Neuropathology and Neuroscience and Bioanalytical Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033 Japan and §Department of Physiology, School of Medicine, Tokyo Women's Medical University, Tokyo, 162-8666 Japan

Mutations in {alpha}-synuclein gene cause familial form of Parkinson disease, and deposition of wild-type {alpha}-synuclein as Lewy bodies occurs as a hallmark lesion of sporadic Parkinson disease and dementia with Lewy bodies, implicating {alpha}-synuclein in the pathogenesis of Parkinson disease and related neurodegenerative diseases. Dopamine neurons in substantia nigra are the major site of neurodegeneration associated with {alpha}-synuclein deposition in Parkinson disease. Here we establish transgenic Caenorhabditis elegans (TG worms) that overexpresses wild-type or familial Parkinson mutant human {alpha}-synuclein in dopamine neurons. The TG worms exhibit accumulation of {alpha}-synuclein in the cell bodies and neurites of dopamine neurons, and EGFP labeling of dendrites is often diminished in TG worms expressing familial Parkinson disease-linked A30P or A53T mutant {alpha}-synuclein, without overt loss of neuronal cell bodies. Notably, TG worms expressing A30P or A53T mutant {alpha}-synuclein show failure in modulation of locomotory rate in response to food, which has been attributed to the function of dopamine neurons. This behavioral abnormality was accompanied by a reduction in neuronal dopamine content and was treatable by administration of dopamine. These phenotypes were not seen upon expression of {beta}-synuclein. The present TG worms exhibit dopamine neuron-specific dysfunction caused by accumulation of {alpha}-synuclein, which would be relevant to the genetic and compound screenings aiming at the elucidation of pathological cascade and therapeutic strategies for Parkinson disease.


Received for publication, May 3, 2005 , and in revised form, October 25, 2005.

* This work was supported by the Ministry of Education, Science, Culture and Sports on Priority Areas-Advanced Brain Science Project and for the Special 21st Century Center of Excellence Program and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{boxs} The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

1 Both authors contributed equally to this work.

2 To whom correspondence should be addressed: Dept. of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo Bunkyoku Tokyo, 113-0033 Japan. Tel.: 81-3-5841-4877; Fax: 81-3-5841-4708; E-mail: iwatsubo{at}mol.f.u-tokyo.ac.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DMMHome page
G. A. Caldwell and K. A. Caldwell
Traversing a wormhole to combat Parkinson's disease
Dis. Model. Mech., July 1, 2008; 1(1): 32 - 36.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.